Healthcare of Ontario Pension Plan Trust Fund Makes New $20.86 Million Investment in Inhibrx Biosciences, Inc. $INBX

Posted by Francis Steltz on Jun 16th, 2026

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 264,000 shares of the company’s stock, valued at approximately $20,856,000. Healthcare of Ontario Pension Plan Trust Fund owned 1.82% of Inhibrx Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of INBX. Strs Ohio purchased a new stake in Inhibrx Biosciences in the first quarter valued at approximately $27,000. Russell Investments Group Ltd. grew its stake in Inhibrx Biosciences by 11.0% during the second quarter. Russell Investments Group Ltd. now owns 29,993 shares of the company’s stock worth $428,000 after buying an additional 2,963 shares during the period. Invesco Ltd. purchased a new stake in Inhibrx Biosciences during the second quarter worth approximately $193,000. Bank of America Corp DE grew its stake in Inhibrx Biosciences by 19.2% during the second quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock worth $130,000 after buying an additional 1,469 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in Inhibrx Biosciences during the second quarter worth approximately $235,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Zacks Research upgraded shares of Inhibrx Biosciences to a “hold” rating in a research note on Thursday, April 9th. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research note on Friday, April 24th. Stifel Nicolaus assumed coverage on shares of Inhibrx Biosciences in a research note on Wednesday, April 8th. They set a “buy” rating and a $150.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Inhibrx Biosciences presently has an average rating of “Hold” and an average price target of $150.00.

Check Out Our Latest Analysis on INBX

Inhibrx Biosciences Stock Performance

NASDAQ:INBX opened at $93.51 on Tuesday. Inhibrx Biosciences, Inc. has a twelve month low of $13.97 and a twelve month high of $155.29. The company has a current ratio of 6.46, a quick ratio of 6.46 and a debt-to-equity ratio of 12.58. The company has a 50-day moving average of $100.95 and a 200-day moving average of $85.11. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -11.15 and a beta of 3.33.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.47). Analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 earnings per share for the current fiscal year.

About Inhibrx Biosciences

(Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.